Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts

British Journal of Cancer

Volumn 88, Issue 4, 2003, Pages 630-635

  Purohit, A ^a   Singh, A ^a   Ghilchik, M W ^b   Serlupi Crescenzi, O ^c   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c Sigma Tau SpA   (Italy)

Author keywords

Aromatase; Breast cancer; Cytokines; Interleukin 6; Prostaglandin E2; Sant 7

Indexed keywords

AROMATASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTAGONIST; PROSTAGLANDIN E2; SANT 7; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; LYMPHOCYTE; MACROPHAGE; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

AROMATASE; BREAST; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6;

EID: 0037463231     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600785     Document Type: Article

References (39)

1. Agarwal V, Bulun SE, Leitch M, Rohrich R, Simpson ER (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81: 3843-3849
2. ATAC Trialist Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139
3. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N (1999) Blocking signalling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumour cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85: 134-144
4. Buzdar AU, Jones SE, Vogel CL, Wotter J, Plourde P, Webster A (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739
5. Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCap prostate cancer cells. Cancer Res 60: 2132-2135
6. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G (1996) Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 56: 4213-4218
7. Elisaf MS, Bairaktari ETh, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlides NA (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510-1513
8. Grodin JM, Siiteri PK, MacDonald PC (1973) Sources of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36: 207-214
9. Harada N, Utsumi T, Takagi Y (1993) Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90: 11312-11316
10. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen 11. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38: 476-479
11. 2 in a murine model of inflammation: possible role of cyclooxygenase 2. Proc Natl Acad Sci USA 93: 4888-4890
12. Honemann D, Chatterjee M, Savino R, Bommert R, Gramatzki M, Dorken B, Bargou RC (2001) The IL-6 receptor antagonist Sant 7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int J Cancer 93: 674-680
13. James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ (1987) Aromatase activity in normal breast and breast tumour tissues: in vivo and in vitro studies. Steroids 50: 269-279
14. Kishimoto T, Akira S, Nagarzaki M, Taga R (1995) Interleukin-6 family of cytokines and gp130. Blood 86: 1243-1254
15. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Mourel-Fournier B, Zhao-Liang L, Mannoni P, Sany J, Baitaille R (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukaemia. Blood 78: 1198-1204
16. Lin D-L, Whitney MC, Yao Z, Keller ET (2001) Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7: 1773-1781
17. Ludwig H, Nacnbaur DM, Fritz E, Krainer M, Huber H (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794-2795
18. Macdiarmid F, Wang D, Duncan LJ, Purohit A, Ghilchik MW, Reed MJ (1994) Stimulation of aromatase activity in breast fibroblasts by tumour necrosis factor α. Mol Cell Endocrinol 106: 17-21
19. Mahendroo MS, Mendelson CR, Simpson ER (1993) Tissue-specific and hormonally controlled alternative promoters regulate aromatase P450 gene expression in human ovary and fetal tissue. J Biol Chem 268: 19463-19470
20. Miller WR (1999) Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocrine Relat Cancer 6: 187-195
21. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW (1997) Subcutaneous adipose tissue releases interleukin-6 but not tumour necrosis factor-α, in vivo. J Clin Endocrinol Metab 82: 4196-4200
22. Parish D, Purohit A, Singh A, Rosankiewicz J, Ghilchik MW, Reed MJ (2001) Peptide inhibition of cytokine-stimulated aromatase activity in breast tissue fibroblasts. J Steroid Biochem Mol Biol 79: 165-172
23. Purohit A, Ghilchik MW, Duncan LJ, Reed MJ (1995) Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 80: 3052-3058
24. Reed MJ, Coldham NG, Patel SR, Ghilchik MW, James VHT (1992) Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol 132: R5-R8
25. Reed MJ, Purohit MJA (1997) Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocrine Rev 18: 701-715
26. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300: 281-190
27. Salvati AL, Lahm A, Paonessa G, Ciliberto G, Toniatti C (1995) Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor α mutated in the predicted gp130-binding interface. J Biol Chem 270: 12242-12249
28. Santen RJ, Harvey HA (1999) Use of aromatase inhibitors in breast cancer. Endocrine Relat Cancer 6: 75-92
29. Schooltink H, Schmitz-Van der Leur H, Heinrich PC, Rose-John S (1992) Upregulation of the interleukin-6 signal transduction protein (gp130) by interleukin-6 and dexamethasone. Eur J Biochem 190: 79-83
30. Singh A, Purohit A, Duncan LJ, Mokbel K, Ghilchik MW, Reed MJ (1997) Control of aromatase in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol 61: 185-192
31. 2. Endocrine-Relat Cancer 6: 139-147
32. Singh A, Purohit A, Wang DY, Duncan LJ, Ghilchik MW, Reed MJ (1995) IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. J Endocrinol 147: R9-R12
33. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T (1989) Interleukin- 6 triggers the association of its receptor with a possible signal transducer protein. Cell 58: 573-581
34. Van Snick J (1990) Interleukin- 6: an overview. Annu Rev Immunol 8: 253-278
35. Wei J, Xu H, Davies JL, Hemmings GP (1992) Increase of plasma IL-6 concentrations with age in healthy subjects. Life Sci 51: 1953-1956
36. Zhang Y, Lin J-X, Vilcek J (1988) Synthesis of interleukin 6 (interferon-beta 2/β cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cAMP. J Biol Chem 263: 6177-6182
37. 2 via cyclic AMP leading to activation of promoter II of the CYP19 (aromatase) gene. J Clin Endocrinol Metab 137: 5739-5742
38. Zhao Y, Mendelson CR, Simpson ER (1995a) Characterisation of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol 9: 340-349
39. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER (1995b) Aromatase P450 gene expression in human adipose tissue. J Biol Chem 270: 16449-16457